Who owns Immunocore Holdings plc (IMCR)? Elite investor 13F holders

5 tracked elite investors reported holding Immunocore Holdings plc as of 2026-06-30, including Caligan Partners, D.E. Shaw, Renaissance Technologies LLC, Bridgewater Associates, Oaktree Capital Management. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

5 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including…

Reported holders and securities, including exits (up to 20)

Reported holders and securities, including exits (up to 20)
InvestorSecurityInstrumentReport periodFiledValueQuantityUnitsChangeSource
Caligan PartnersIMMUNOCORE HLDGS PLCSHARE2026-06-302026-08-14 00:00:0043856815.00 USD1381317.000000SharesbuyOriginal filing
D.E. ShawIMMUNOCORE HLDGS PLCSHARE2026-06-302026-08-14 00:00:0012862433.00 USD405116.000000SharesaddOriginal filing
Renaissance Technologies LLCIMMUNOCORE HLDGS PLCSHARE2026-06-302026-08-13 00:00:003251200.00 USD102400.000000SharesreduceOriginal filing
Bridgewater AssociatesIMMUNOCORE HLDGS PLCSHARE2026-06-302026-08-14 00:00:001165447.00 USD36707.000000SharesaddOriginal filing
Oaktree Capital ManagementIMMUNOCORE HOLDINGS PLCSHARE2026-06-302026-08-14 00:00:00766360.00 USD833000.000000PrincipalholdOriginal filing

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

How to read the data · Disclaimer

Read as Markdown